JP6630364B2 - 水溶性プロドラッグ - Google Patents

水溶性プロドラッグ Download PDF

Info

Publication number
JP6630364B2
JP6630364B2 JP2017549601A JP2017549601A JP6630364B2 JP 6630364 B2 JP6630364 B2 JP 6630364B2 JP 2017549601 A JP2017549601 A JP 2017549601A JP 2017549601 A JP2017549601 A JP 2017549601A JP 6630364 B2 JP6630364 B2 JP 6630364B2
Authority
JP
Japan
Prior art keywords
group
optionally substituted
bis
substituted
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017549601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509441A5 (enExample
JP2018509441A (ja
Inventor
坂　仁志
仁志 坂
正児 上岡
正児 上岡
裕介 澤山
裕介 澤山
チャン チア リー，
チャン チア リー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JP2018509441A publication Critical patent/JP2018509441A/ja
Publication of JP2018509441A5 publication Critical patent/JP2018509441A5/ja
Application granted granted Critical
Publication of JP6630364B2 publication Critical patent/JP6630364B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017549601A 2015-03-27 2016-03-25 水溶性プロドラッグ Expired - Fee Related JP6630364B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139077P 2015-03-27 2015-03-27
US62/139,077 2015-03-27
PCT/IB2016/051706 WO2016157052A1 (en) 2015-03-27 2016-03-25 Water-soluble prodrugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019221478A Division JP6885999B2 (ja) 2015-03-27 2019-12-06 水溶性プロドラッグ

Publications (3)

Publication Number Publication Date
JP2018509441A JP2018509441A (ja) 2018-04-05
JP2018509441A5 JP2018509441A5 (enExample) 2019-02-14
JP6630364B2 true JP6630364B2 (ja) 2020-01-15

Family

ID=55650622

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017549601A Expired - Fee Related JP6630364B2 (ja) 2015-03-27 2016-03-25 水溶性プロドラッグ
JP2019221478A Expired - Fee Related JP6885999B2 (ja) 2015-03-27 2019-12-06 水溶性プロドラッグ
JP2021081570A Pending JP2021120401A (ja) 2015-03-27 2021-05-13 水溶性プロドラッグ

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019221478A Expired - Fee Related JP6885999B2 (ja) 2015-03-27 2019-12-06 水溶性プロドラッグ
JP2021081570A Pending JP2021120401A (ja) 2015-03-27 2021-05-13 水溶性プロドラッグ

Country Status (7)

Country Link
US (3) US10183925B2 (enExample)
EP (1) EP3274346A1 (enExample)
JP (3) JP6630364B2 (enExample)
CN (1) CN107660202B (enExample)
CA (1) CA2980845A1 (enExample)
TW (1) TWI710555B (enExample)
WO (1) WO2016157052A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10183925B2 (en) * 2015-03-27 2019-01-22 Boston Biomedical, Inc. Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer
US10738023B2 (en) 2016-03-25 2020-08-11 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, and said related substance
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
WO2018213424A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
JPWO2019059344A1 (ja) * 2017-09-22 2020-11-26 大日本住友製薬株式会社 化学活性化型水溶性プロドラッグ
US20220304972A1 (en) * 2019-08-23 2022-09-29 Sumitomo Dainippon Pharma Co., Ltd. Combination therapy and biomarker indicating efficacy thereof
FR3112145A1 (fr) * 2020-07-03 2022-01-07 Nanotracks Diagnostics Derives uree de macrolides polyeniques, composes chimiques particuliers susceptibles d’etre utilises pour obtenir ces derives uree, compositions les contenant et utilisations
WO2022003181A1 (fr) * 2020-07-03 2022-01-06 Nanotracks Diagnostics Derivés urée de l'amphotéricine amb, compositions les contenant et leurs utilisations, dérivés isocyanate d'alkyle omega-aminés et leur utilisation pour obtenir lesdits dérivés urée
CN112194598B (zh) * 2020-10-15 2021-12-21 郑州猫眼农业科技有限公司 3-(叔丁氧基羰基-r氧基羰基甲基-氨基)-丙酸酯的制备方法
CN118302407A (zh) * 2021-11-08 2024-07-05 旭化成株式会社 羰基化合物、羰基化合物的制造方法、异氰酸酯化合物的制造方法以及异氰酸酯组合物
JP7680560B2 (ja) * 2021-11-08 2025-05-20 旭化成株式会社 カルボニル化合物、イソシアネート化合物の製造方法、及びイソシアネート組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104586832B (zh) 2007-09-10 2018-02-16 北京强新生物科技有限公司 用于癌症治疗的组合物和方法
US9150530B2 (en) * 2011-03-04 2015-10-06 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Esters of 4, 9-dihydroxy-naphtho [2, 3-b] furans for disease therapies
JP2015506990A (ja) * 2012-02-17 2015-03-05 ゾウシャン ハイジョンジョウ シンシェン ファーマシューティカルズ カンパニー リミテッドＺｈｏｕｓｈａｎ Ｈａｉｚｈｏｎｇｚｈｏｕ Ｘｉｎｓｈｅｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． ４，９−ジヒドロキシ−ナフト［２，３−ｂ］フラン脂肪族酸エステルの誘導体の水性ナノ粒子懸濁液を調製する方法
GB201203705D0 (en) 2012-03-02 2012-04-18 Kappa Bioscience As Prodrugs
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
US10183925B2 (en) * 2015-03-27 2019-01-22 Boston Biomedical, Inc. Substituted naphtho[2,3-b]furans as water-soluble prodrugs for preventing and/or treating cancer

Also Published As

Publication number Publication date
JP2021120401A (ja) 2021-08-19
HK1243079A1 (zh) 2018-07-06
CA2980845A1 (en) 2016-10-06
US20200392098A1 (en) 2020-12-17
TW201639824A (zh) 2016-11-16
US20190084955A1 (en) 2019-03-21
JP2020055854A (ja) 2020-04-09
JP6885999B2 (ja) 2021-06-16
CN107660202B (zh) 2021-12-24
US20180111914A1 (en) 2018-04-26
TWI710555B (zh) 2020-11-21
WO2016157052A1 (en) 2016-10-06
US11414394B2 (en) 2022-08-16
US10183925B2 (en) 2019-01-22
CN107660202A (zh) 2018-02-02
US10800752B2 (en) 2020-10-13
EP3274346A1 (en) 2018-01-31
JP2018509441A (ja) 2018-04-05

Similar Documents

Publication Publication Date Title
JP6885999B2 (ja) 水溶性プロドラッグ
JP7829523B2 (ja) 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用
TWI843372B (zh) 用於降解突變kras蛋白之化合物及其應用
AU2019356565B2 (en) Prodrug modulators of the integrated stress pathway
ES2944573T3 (es) Antagonistas de TLR7/8 y usos de los mismos
ES2588680T3 (es) Compuestos de tiazolopirimidina
EP3041822B1 (en) Compounds useful as immunomodulators
JP2023065588A (ja) Ｔｌｒ７／８アンタゴニストおよびそれらの使用
JP6619420B2 (ja) Ｍｅｔａｐ−２阻害剤としてのピロリジノン誘導体
CN105246887B (zh) 香豆素衍生物以及用于治疗过度增生性疾病的方法
EA028059B1 (ru) Твердые формы n-((s)-2,3-дигидроксипропил)-3-(2-фтор-4-йодфениламино)изоникотинамида
WO2021172359A1 (ja) Ｃｄｋ９阻害剤プロドラッグ及びそれを内封するリポソーム
HK1243079B (zh) 水溶性前药
JP2005023007A (ja) 複素環化合物およびその用途
US20240368138A1 (en) Self degradation-type cdk9 inhibitor prodrug and liposome encapsulating same
BR122021006373B1 (pt) Antagonistas de tlr7/8 policíclicos, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191018

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191017

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191126

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191206

R150 Certificate of patent or registration of utility model

Ref document number: 6630364

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees